Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common
complications of type 2 diabetes and leading causes of liver disease in the US and Europe.
The prevalence of NAFLD and NASH are expected to become a major cause of liver disease
related deaths and liver transplantation. Currently, there are no specific therapies that
alter the natural history of NAFLD.Preliminary evidence suggests that exenatide (Byetta®) may
have several beneficial direct and indirect effects on NAFLD and liver lipid metabolism.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Amylin Pharmaceuticals, LLC. Eli Lilly and Company